Abstract
Recent studies suggest that 40Hz photoacoustic stimulation is beneficial for improving cognition, and is safe and effective in patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI). It has been reported that the healthy population responds more strongly to the 40 Hz intervention compared to MCI and AD patients. Therefore, the aim of this study was to explore the effectiveness of 40 Hz photoacoustics in preventing cognitive impairment and improving sleep quality in the healthy population.
Four weeks of 40 Hz intervention significantly improved sleep quality (PSQI) (p=0.028) and enhanced functional connectivity in the hippocampus and default mode network (DMN) (in the cognitively impaired population, functional connectivity showed a decreasing trend). These results were consistent with findings from the FDA clinical trial on MCI/AD patients that showed enhanced connectivity of the core regions PCC and mPFC within the DMN network. No serious adverse effects were reported throughout the intervention.
This study is the first to validate the efficacy and safety of a 40 Hz photoacoustic intervention in a healthy population, suggesting its potential in preventing cognitive decline in a healthy population.
Competing Interest Statement
Zhuping Gong, Kaixiu Jin, Junhu Teng, Ziyu Liu, Huajiang Zhang, Qian Xu, Yanling Chen, and Cong Fang are staff members of Hangzhou Shudan Healthcare Technology Co. Ltd., which aims to develop gamma stimulation-related products. Other authors declare no other competing financial interests.
Clinical Trial
ChiCTR2300071558
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants gave written consent and the study was approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
